Time to first treatment in the different prognostic subgroups
Characteristic . | Category . | Total . | Patients treated . | Median TTFT, mo (95% CI) . | Treatment free at 5 y (95% CI) . | P . |
---|---|---|---|---|---|---|
All patients | 351 | 147 | 72 (60-101) | 0.56 (0.50-0.62) | ||
IgVH | Mutated | 142 | 40 | 154 (100-> 250) | 0.73 (0.64-0.82) | < .0001 |
Unmutated | 129 | 79 | 45 (33-58) | 0.37 (0.29-0.49) | ||
CD38 | Negative | 252 | 89 | 101 (70-> 250) | 0.60 (0.53-0.68) | < .0001 |
Positive | 84 | 55 | 34 (21-66) | 0.37 (0.27-0.51) | ||
ZAP-70 | Negative | 153 | 51 | 122 (79-> 250) | 0.65 (0.57-0.75) | < .0001 |
Positive | 133 | 78 | 43 (32-58) | 0.38 (0.29-0.49) | ||
β2-microglobulin | < 4 mg/L | 262 | 92 | 101 (69-> 250) | 0.59 (0.52-0.67) | .0003 |
≥ 4 mg/L | 87 | 55 | 47 (36-72) | 0.46 (0.36-0.60) | ||
CCL3 | Low | 177 | 35 | > 250 (181-> 250) | 0.75 (0.67-0.84) | < .0001 |
High | 174 | 112 | 40 (32-59) | 0.40 (0.33-0.49) | ||
CCL4 | Low | 180 | 49 | 181 (101-> 250) | 0.66 (0.58-0.76) | .0002 |
High | 171 | 98 | 58 (40-72) | 0.47 (0.40-0.57) |
Characteristic . | Category . | Total . | Patients treated . | Median TTFT, mo (95% CI) . | Treatment free at 5 y (95% CI) . | P . |
---|---|---|---|---|---|---|
All patients | 351 | 147 | 72 (60-101) | 0.56 (0.50-0.62) | ||
IgVH | Mutated | 142 | 40 | 154 (100-> 250) | 0.73 (0.64-0.82) | < .0001 |
Unmutated | 129 | 79 | 45 (33-58) | 0.37 (0.29-0.49) | ||
CD38 | Negative | 252 | 89 | 101 (70-> 250) | 0.60 (0.53-0.68) | < .0001 |
Positive | 84 | 55 | 34 (21-66) | 0.37 (0.27-0.51) | ||
ZAP-70 | Negative | 153 | 51 | 122 (79-> 250) | 0.65 (0.57-0.75) | < .0001 |
Positive | 133 | 78 | 43 (32-58) | 0.38 (0.29-0.49) | ||
β2-microglobulin | < 4 mg/L | 262 | 92 | 101 (69-> 250) | 0.59 (0.52-0.67) | .0003 |
≥ 4 mg/L | 87 | 55 | 47 (36-72) | 0.46 (0.36-0.60) | ||
CCL3 | Low | 177 | 35 | > 250 (181-> 250) | 0.75 (0.67-0.84) | < .0001 |
High | 174 | 112 | 40 (32-59) | 0.40 (0.33-0.49) | ||
CCL4 | Low | 180 | 49 | 181 (101-> 250) | 0.66 (0.58-0.76) | .0002 |
High | 171 | 98 | 58 (40-72) | 0.47 (0.40-0.57) |